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The Systolic Blood Pressure Intervention Trial (SPRINT)
included a subset of 2,636 adults aged 75 years and older
randomized to a systolic blood pressure (SBP) target
of <120 mmHg or to <140 mmHg (1). Of the persons
randomized to a SBP <120 mmHg, 33.4% were frail. Of
the persons randomized to a SBP <140 mmHg, 28.4%
were frail. The primary composite outcome of nonfatal
myocardial infarction, acute coronary syndrome not
resulting in a myocardial infarction, nonfatal stroke, nonfatal
acute decompensated heart failure, and cardiovascular death
was lowered 34% and all-cause mortality lowered 33% by a
SBP <120 mmHg (1). These outcomes were not different in
frail persons. These very elderly adults with a SBP <120 mmHg
also had a 37% lowering of nonfatal heart failure and a 32%
lowering of the primary outcome plus all-cause mortality (1).
The absolute rate of serious adverse events was 2.4% in the
lower SBP treatment group versus 1.4% in the standard
SBP treatment group. Orthostatic hypotension occurred in
21.0% in the lower SBP treatment group versus 21.8% in
the standard SBP treatment group (1). This study did not
include persons living in a nursing home or persons with
diabetes, prior stroke, symptomatic heart failure, or a left
ventricular ejection fraction (LVEF) <35% (1).
The American College of Cardiology (ACC)/American
Heart Association (AHA) 2017 guidelines will have to
answer by expert medical opinion many questions not
answered by SPRINT. What should the SBP goal and
the diastolic blood pressure (DBP) goal be in adults with
diabetes, an acute coronary syndrome, prior stroke or
transient ischemic attack, heart failure with a preserved
or low LVEF, a LVEF below 35%, younger than 50 years,
at low-risk for cardiovascular events, or those living in a
nursing home? The 2015 AHA/ACC/American Society
of Hypertension scientific statement on treatment of
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hypertension in patients with coronary artery disease
recommends a blood pressure (BP) goal of <140/90 mmHg
in adults with stable angina, an acute coronary syndrome,
and heart failure but states that a BP goal of <130/80 mmHg
may be appropriate , especially in those with a prior
myocardial infarction or stroke or at high risk for developing
either (2).
The DBP should not be lowered to <60 mmHg in
any adult with coronary artery disease with myocardial
ischemia, diabetes, or age older than 60 years of age (3,4).
The SBP should not be lowered to <110 mmHg in these
adults (3). Cardiovascular risk should be assessed to guide
the diagnosis and therapy of hypertension (5). Although
many hypertension experts recommend treating patients
with cardiovascular risk factors with hypertension to a BP
goal of <120/80 mmHg (6), not all recommend this goal (7).
Hypertension in high-risk adults could be defined as a
BP ≥130/80 mmHg with a threshold of treatment of
130/80 mmHg with a goal SBP of < 120 mmHg (8).
The Orthostatic Hypotension in Diabetics in the Action
to Control Cardiovascular Risk in Diabetes Blood Pressure
(ACCORD BP) trial investigated the prevalence, incidence,
and prognostic significance of orthostatic hypotension in
the ACCORD BP trial (9,10). The participants in this trial
were at high risk for having orthostatic hypotension because
they had type 2 diabetes, had hypertension, and were
treated with antihypertensive drugs. The persons in this
trial were a randomized to treatment with antihypertensive
drugs to lower the SBP to <120 mmHg or to <140 mmHg.
After 1 year, the SBP was 119.3 mmHg with intensive
blood pressure control versus 133.5 mmHg with standard
antihypertensive drug treatment (9).
At 4 years, the prevalence of orthostatic hypotension was
12.2% in hypertensive diabetics treated to a SBP <120 mmHg
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versus 13.5% in hypertensive diabetics treated to a
SBP <140 mmHg (9). At 4 years, the incidence of
orthostatic hypotension was 9.9% in hypertensive diabetics
treated to a SBP <120 mmHg versus 11.0% in hypertensive
diabetics treated to a SBP <140 mmHg (9). Orthostatic
hypotension was associated with a 62% increase in all-cause
mortality and with a 85% increase in heart failure death or
hospitalization (9).
A randomized clinical trial using a similar number
of participants and design used in SPRINT needs to be
performed in older hypertensive diabetics to investigate
whether the SBP goal should be <120 or <140 mmHg
in hypertensive diabetics (10). The Orthostatic Hypotension
in ACCORD BP study reassures us that hypertensive
diabetics treated to a SBP goal of <120 mmHg will not have
a higher prevalence or incidence of orthostatic hypotension
than hypertensive diabetics treated to a SBP goal of <140
mmHg (9,10).
A meta-analysis of 19 randomized antihypertensive drug
trials with 44,989 participants demonstrated that persons
treated with more intensive BP lowering treatment had a
mean BP of 133/76 mmHg compared to 140/81 mmHg
with less intensive BP treatment group (11). At 3.8-year
mean follow-up, compared with less intensive BP treatment,
more intensive BP treatment lowered major cardiovascular
events 14%, myocardial infarction 13%, stroke 22%,
albuminuria 10%, and retinopathy progression 19% (11).
A meta-analysis of 123 antihypertensive drug trials
including 613,815 participants demonstrated that every
10 mmHg decreases in SBP lowered major cardiovascular
disease events 20%, coronary heart disease 17%, stroke 27%,
heart failure 28%, and all-cause mortality 13% (12).
The Heart Outcomes Prevention Evaluation (HOPE)-3
trial randomized 12,705 participants at intermediate risk
who did not have cardiovascular disease with a mean BP
of 138.1/81.9 mmHg to receive candesartan 16 mg daily
plus hydrochlorothiazide 12.5 mg daily or placebo (13).
The decrease in BP was 6.0/3.0 mmHg greater in the BP
treatment group than in the placebo group. Median
follow-up was 5.6 years. The first coprimary endpoint of
a composite of cardiovascular death, nonfatal myocardial
infarction, or nonfatal stroke was insignificantly lowered 7%
by drug treatment (13). The second coprimary endpoint
additionally included resuscitated cardiac arrest, heart
failure, and revascularization and was insignificantly lowered
5% by drug treatment. Participants in the upper third of
SBP (>143.5 mmHg) had a significant reduction in the first
coprimary endpoint of 23% and in the second coprimary
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endpoint of 28% if they were treated with candesartan plus
hydrochlorothiazide (13). Reasons for the difference in
results between the SPRINT trial and the HOPE-3 trial are
discussed by their investigators (14,15).
The National Heart Foundation of Australia 2016
guideline for management of hypertension recommends
ambulatory and/or home BP monitoring if the clinic BP
is ≥140/90 mmHg as out-of-clinic BP is a stronger
predictor of outcome (16). This guideline also recommends
in selected high cardiovascular risk populations a SBP goal
of <120 mmHg to improve cardiovascular outcomes. Close
follow-up is recommended in these persons to identify
treatment-related adverse effects including hypotension,
syncope, electrolyte abnormalities, and acute kidney injury (16).
The 2016 Canadian hypertension guideline recommends
for high-risk patients aged 50 years and older with SBP
levels of 130 mmHg and higher intensive BP management
to target a SBP goal of 120 mmHg and lower (17). Intensive
BP management should be guided by automated office
BP measurements. Clinical indications defining high-risk
patients for consideration for intensive BP treatment are
clinical or subclinical cardiovascular disease or chronic kidney
disease (nondiabetic nephropathy, proteinuria <1 gram/day,
estimated glomerular filtration rate 20–59 mL/min per 1.73 m2)
or estimated 10-year global cardiovascular risk ≥15% or
age ≥75 years (17). Persons with 1 or more of these clinical
indications should consent to intensive BP treatment (17).
At 24-year median follow-up of the Trials of Hypertension
Prevention, in which 744 phase I and 2,382 phase II persons
were randomized to sodium reduction or control, there was
an increased risk of all-cause mortality for high sodium
intake and a direct relationship with all-cause mortality,
even at the lowest levels of sodium intake (18). The hazard
ratio per unit increase in sodium/potassium ratio was 1.13 (18).
Using data from a population-based 11-cohort
International Database on Ambulatory Blood Pressure
Monitoring in Relation to Cardiovascular Outcomes,
a study compared daytime ambulatory blood pressure
monitoring with conventional BP measurements in 653
untreated adults with white coat hypertension and 653
normotensive control adults (19). Median follow-up was
10.6 years, This study showed that after accounting for
age, the size of the white coat effect was not influenced
by the severity of risk for cardiovascular disease or the
presence of past cardiovascular disease events (19). The
risk of cardiovascular disease in most adults with white
coat hypertension was comparable to age-and risk-adjusted
normotensive control persons (19).
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